| # | Drug | Count |
|---|---|---|
| 0 | RITUXIMAB | 313 |
| 1 | SATRALIZUMAB | 305 |
| 2 | INEBILIZUMAB | 130 |
| 3 | ECULIZUMAB | 128 |
| 4 | METHYLPREDNISOLONE | 109 |
| 5 | PREDNISOLONE | 108 |
| 6 | PREDNISOLONE ORAL | 108 |
| 7 | PREDNISOLONE ORAL SOLUTION | 108 |
| 8 | PREDNISONE | 102 |
| 9 | MYCOPHENOLATE MOFETIL | 97 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | SATRALIZUMAB | 305 | 0.1705 |
| 1 | OMEPRAZOLE 20 MG | 1 | 0.0049 |
| 2 | RITUXIMAB-ABBS | 23 | 0.0045 |
| 3 | LIFILEUCEL | 1 | 0.0035 |
| 4 | PENCICLOVIR | 1 | 0.0028 |
| 5 | FINGOLIMOD HYDROCHLORIDE | 14 | 0.0027 |
| 6 | SAXAGLIPTIN | 4 | 0.0027 |
| 7 | ESTRADIOL AND NORETHINDRONE ACETATE | 1 | 0.0026 |
| 8 | COCAINE HYDROCHLORIDE | 1 | 0.0026 |
| 9 | HYALURONATE SODIUM | 4 | 0.0026 |
| # | Drug class | Count |
|---|---|---|
| 0 | CD20-directed Cytolytic Antibody [EPC] | 352 |
| 1 | Corticosteroid [EPC] | 287 |
| 2 | Complement Inhibitor [EPC] | 128 |
| 3 | Purine Antimetabolite [EPC] | 87 |
| 4 | Nonsteroidal Anti-inflammatory Drug [EPC] | 65 |
| 5 | Interleukin-6 Receptor Antagonist [EPC] | 51 |
| 6 | Proton Pump Inhibitor [EPC] | 46 |
| 7 | Mood Stabilizer [EPC] | 33 |
| 8 | Folate Analog Metabolic Inhibitor [EPC] | 32 |
| 9 | Histamine-1 Receptor Antagonist [EPC] | 31 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Complement Inhibitor [EPC] | 128 | 0.0023 |
| 1 | CD20-directed Cytolytic Antibody [EPC] | 352 | 0.0011 |
| 2 | Purine Antimetabolite [EPC] | 87 | 0.0009 |
| 3 | Sphingosine 1-phosphate Receptor Modulator [EPC] | 12 | 0.0009 |
| 4 | Lymphocyte Growth Factor [EPC] | 1 | 0.0008 |
| 5 | Human Immunoglobulin G [EPC] | 16 | 0.0008 |
| 6 | CD52-directed Cytolytic Antibody [EPC] | 11 | 0.0006 |
| 7 | Antimetabolite Immunosuppressant [EPC] | 9 | 0.0004 |
| 8 | Interleukin-6 Receptor Antagonist [EPC] | 51 | 0.0004 |
| 9 | Histamine-1 Receptor Antagonist [EPC] | 31 | 0.0004 |